Drug Topics, Digital Edition, June 2012

In a phase 3 study, 57% of patients treated with icotrokinra achieved an Investigator's Global Assessment score of 1 or 0 and a grade 2 or more improvement at week 16.

President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.

The order is set to make patients’ prescription costs similar to other nations with the lowest-priced drugs in the world.

In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.

Douglas Hoey, CEO of NCPA, discusses what independent pharmacies can do to handle an influx of patients and what the chain’s situation means for the pharmacy landscape.

Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss the basics of AI and how it’s assisting with compliance.